Haier Biomedical Unveils Comprehensive Laboratory Solutions at analytica Munich 2026

On April 10, 2026, Haier Biomedical, a global leader in life sciences solutions, debuted its extensive range of laboratory solutions at the analytica Munich 2026 under the theme "In Europe, for Europe." This exhibition marks a significant step in the company’s strategy to enhance its local presence in Europe, backed by a robust operational network and recent achievements in key markets across the continent.

Haier Biomedical is transitioning from a traditional equipment supplier to a holistic provider of scenario-based solutions for laboratories. The company now offers end-to-end solutions tailored for biobanks, research laboratories, and pharmacies, which cover all stages from sample collection, storage, monitoring, to management. Among the products on display at analytica 2026 were CO₂ incubators, biological safety cabinets, centrifuges, pharmacy refrigeration units, liquid nitrogen tanks, autoclaves, and newly launched incubator shakers. These shakers are specifically designed for cell culture in suspension with continuous oscillation and precise temperature control, alongside a freeze-dryer aimed at efficient sample drying.

One of the standout innovations highlighted at the event was the UltraEco ULT low-temperature freezer series, equipped with Eco-Drive technology that delivers 30% greater efficiency than industry standards. In addition to biobanking solutions revealed during the event, Haier Biomedical now provides fully integrated and automated workflows for sample collection, storage, and monitoring. These solutions effectively address the real-world challenges of sample integrity, operational efficiency, and data traceability.

The company views globalization not merely as a one-way export of products but as a way to strengthen its presence in local markets. Haier has adopted a "one country, one strategy" approach, establishing operational structures in 18 countries worldwide and acquiring over 400 local product certifications, with local teams accounting for more than 40% of its global workforce. This strategy has allowed Haier Biomedical to achieve market leadership among Chinese brands in six countries, including Italy, where the company plans to set up a subsidiary to enhance local service capabilities and provide more comprehensive value to regional users.

In the UK, Haier Biomedical executed a comprehensive delivery of 64 customized biological safety cabinets to Queen Mary University of London within 24 hours. In Italy, the company supplied a local hospital with a customized smart blood resource management system, U-Blood, integrating smart resource management into the European healthcare system. Meanwhile, in Germany, Haier provided -150°C cryogenic freezers and BPST ULT freezers to leading local universities, combining hydrocarbon cooling technology with exceptionally quiet operation to enhance research safety and efficiency.

Analytica 2026 represents a fundamental strategic shift for Haier Biomedical—from mere product exportation to co-creating an ecosystem. Through a model combining technology, local presence, and an ecosystem approach, Haier Biomedical is embarking on a new chapter in the globalization of its life sciences segment. Moving forward, Haier Biomedical will continue to deepen its presence in the European market, supporting global expansion through a strong focus on local market presence, and aims to become a trusted brand in life sciences for users around the world. For more information, visit Haier Biomedical.